Cellectis S.A. (CLLS) vs Rallybio Corporation (RLYB)

Cellectis S.A. and Rallybio Corporation are both Biotechnology companies. Cellectis S.A. and Rallybio Corporation are of similar size ($90.4M and $90.2M). Cellectis S.A. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.1×. Rallybio Corporation grew revenue faster over the last twelve months: 1.18% against 0.61%. Rallybio Corporation has the higher net margin (0.00% vs −102.3%) and the lower return on invested capital (−1,052.0% vs 0.00%). Across the 16 metrics below, Rallybio Corporation leads on 13 and Cellectis S.A. on 3.

Valuation

Metric CLLS RLYB Biotechnology median
P/E n/m 2.11 8.68
P/S 1.99 113.05 10.29
P/B 3.09 1.03 2.40
Price to free cash flow n/m 3.64 20.52
EV/EBITDA n/m n/m 0.68
EV/Sales 0.53 4.83 10.15
Earnings yield (51.91%) 47.35% (28.86%)
Free cash flow yield (36.43%) 27.51% (22.44%)

Profitability

Metric CLLS RLYB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (90.88%) 0.00% 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) 64.86% (56.66%)
Return on assets (21.02%) 61.12% (49.22%)
Return on invested capital 0.00% (1,052.03%) 0.00%

Growth

Metric CLLS RLYB Biotechnology median
Revenue growth (TTM) 0.61% 1.18% 5.64%
EPS growth (last fiscal year) (63.41%) 85.06% 30.08%
Revenue growth, 5-year CAGR (0.70%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS RLYB Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 27.26 4.72
Net debt to EBITDA 9.54 1.63 0.96

Dividend

Metric CLLS RLYB Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CLLS RLYB Biotechnology median
Market cap 90.41m 90.23m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack